Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Treatment of multiple sclerosis with anti-CD20 antibodies.
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
The INCAT disability score: A critical analysis of its measurement properties.
Raloxifene Suppresses Experimental Autoimmune Encephalomyelitis and NF-κB-Dependent CCL20 Expression in Reactive Astrocytes.
A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity.
The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis.
Galectin-1 for neuroprotection?
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Helminth therapy and multiple sclerosis.
Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis.
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Pilates based core stability training in ambulant individuals with multiple sclerosis: Protocol for a multi-centre randomised controlled trial.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis.
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.
Receptos, Inc. - Current Report: United States Securities and Exchange Commission Form 8-K
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.
Cranial neuropathies in multiple sclerosis defined by magnetic resonance imaging and fludeoxyglucose f 18 positron emission tomography.
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.

Pages